13.23
Sistemi di somministrazione dei farmaci a rilascio modificato: a velocità programmata II
I sistemi di rilascio dei farmaci a velocità programmata rilasciano i farmaci in modo controllato per mantenere livelli terapeutici. I tre principali…
I sistemi di somministrazione di farmaci programmati a velocità possono seguire tre design: serbatoio, matrice o ibrido.
I sistemi a serbatoio racchiudono il nucleo del farmaco all'interno di un film o membrana di controllo della velocità.
I tipi non gonfianti utilizzano polimeri di etilcellulosa e polimetacrilato per controllare il rilascio del farmaco tramite spessore, insolubilità, lenta dissoluzione o porosità. I tipi controllati dal gonfiore spesso usano polimeri come l'HPMC per ritardare il rilascio del farmaco fino all'idratazione della membrana.
I sistemi matriciali incorporano il farmaco in un materiale ritardante di rilascio.
Le matrici idrofile utilizzano polimeri gonfianti come l'HPMC, mentre le matrici idrofobiche usano cere o cellulosa etil. Le matrici idrofobiche possono essere porose, con il farmaco mescolato nel polimero, oppure non porose, con il farmaco disperso nel polimero fuso.
I sistemi ibridi incorporano il farmaco in una matrice rivestita con un materiale ritardante di rilascio, che viene ulteriormente rivestito con un polimero che controlla il rilascio. Questo progetto combina il rilascio costante dei sistemi a serbatoio con la durabilità dei dispositivi a matrice, controllando efficacemente il rilascio del farmaco.
View the full transcript and gain access to JoVE Core videos
Q1: What are the three main designs of rate-programmed drug delivery systems?
Rate-programmed drug delivery systems follow three designs: reservoir, matrix, and hybrid. Reservoir systems enclose the drug core within a rate-controlling membrane. Matrix systems embed the drug in a release-retarding material. Hybrid systems combine both approaches by embedding drug in a matrix and coating it with a polymer membrane, merging the consistent release of reservoir systems with the structural durability of matrix systems.
Q2: How do non-swelling reservoir systems control drug release?
Non-swelling reservoir systems use polymers like ethyl cellulose and polymethacrylates that do not hydrate in aqueous media. These polymers control drug release through membrane thickness, insolubility, slow dissolution, or porosity. This design is used in coated particles, pellets, or tablets to achieve predictable, sustained drug delivery without requiring membrane hydration.
Q3: What is the difference between hydrophilic and hydrophobic matrix systems?
Hydrophilic matrices use water-swellable polymers like HPMC that form porous structures and allow drug diffusion through the swollen matrix. Hydrophobic matrices use slowly soluble or insoluble materials like waxes or ethyl cellulose. Hydrophobic matrices can be porous, with drug mixed into polymer particles, or nonporous, with drug dispersed in molten polymer for controlled release.
Q4: How do swelling-controlled reservoir systems delay drug release?
Swelling-controlled reservoir systems use polymers such as HPMC that hydrate in aqueous media. Drug release begins only after the membrane absorbs water and hydrates, resulting in a delayed onset followed by steady release. This design allows precise timing of drug delivery initiation, making it useful for drugs requiring delayed therapeutic action.
Q5: What advantage do hybrid drug delivery systems offer over single-design systems?
Hybrid systems embed drug in a matrix and coat it with a polymer membrane, combining the consistent drug release of reservoir systems with the structural durability of matrix systems. This design provides superior control over drug delivery by leveraging the steady-state kinetics of reservoirs while maintaining the mechanical stability and longevity of matrix devices.
Q6: How does membrane thickness affect drug release in reservoir systems?
In non-swelling reservoir systems, membrane thickness is a critical parameter controlling drug release rate. Thicker membranes slow drug diffusion through the polymer, extending release duration, while thinner membranes accelerate release. By adjusting ethyl cellulose or polymethacrylate membrane thickness, manufacturers can precisely program drug release kinetics to match therapeutic requirements.
Q7: What role does porosity play in controlling drug release from matrix systems?
Porosity in matrix systems, particularly in hydrophobic matrices, creates pathways for drug diffusion and dissolution. Porous hydrophobic matrices mix drug and polymer particles, allowing fluid penetration and drug release through interconnected pores. Nonporous systems rely on drug solubility and polymer erosion, offering different release profiles suited to specific drug properties and therapeutic goals.